Baseline prevalence and incidence and risk factors for new-onset drug induced hearing loss in adults receiving drug-resistant tuberculosis (DR-TB) treatment in Khayelitsha, South Africa

Treatment for drug-resistant tuberculosis (DR-TB) is longer and associated with more significant side-effects than drug susceptible TB. Second line injectable therapy using kanamycin, amikacin or capreomycin is associated with irreversible hearing loss. There is a scarcity of literature regarding the frequency of hearing loss as well as associated risk factors, particularly with long term use. This study aimed to determine the incidence and risk factors for hearing loss among patients receiving second line injectable drugs.

Grantor dc:publisher.institution

Department of Public Health and Family Medicine

Year dc:date.issued

2013

Author dc:creator

• Njuguna, Christine Wanjiku

Advisors dc:contributor.advisor

• Cox, Helen
• Boulle, Andrew

Language dc:language.iso

eng

Handle dc:identifier.uri

http://hdl.handle.net/11427/10625

OAI identifier oai:identifier

oai:open.uct.ac.za:11427/10625